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O1. Introduction
Melanoma is the most serious type of skin cancer. It originates in
pigment-producing melanocytes1. Melanoma has become one of the
most common cancers in the world. Due to its high potential for
metastasis, individuals with this disease have a poor prognosis and
low survival rates2. Melanoma at advanced stages is often resistant to
conventional radiation therapy and chemotherapy as a result of
multiple mechanisms, including increased DNA repair and alterations
of several key regulatory genes or proteins3,4. Therefore, therapeutic
approaches directed at speciﬁc signaling pathways or mutations in
melanoma have been employed5,6. One of the targets is the RAS-
activated serine-threonine protein kinase B-raf (BRAF). It plays a
central role in the regulation of the mitogen-activated protein kinase
(MAPK) signaling pathway that regulates cell division, proliferation
and differentiation in melanoma7,8. The consequence of mutations is
the constitutive activation of the BRAF kinase and downstream
MAPK signaling that promotes unregulated cell proliferation and cell
invasion. In melanoma patients, the BRAF(V600E; valine to
glutamate) substitution is the most common mutation9, which is
associated with poor clinical outcome10 and brain metastases11. Since
this mutation is found in approximately 40–60% of melanoma
patients8, improved clinical outcome is expected for melanoma
patients with inhibition of BRAF(V600E) signaling8–10.N
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Dabrafenib2. Vemurafenib treatment for BRAF (V600E) mutation
patients with advanced or metastatic melanoma
Vemurafenib (PLX4032, Zelborafs) is a small molecule inhibitor of
the cytoplasmic BRAF serine-threonine kinase (chemical structure
given in Fig. 1), which in 2011 was approved by the US Food and
Drug Administration (FDA) for treatment of metastatic and unresect-
able melanomas that carry an activating BRAF(V600E) mutation12–
14. Moreover, in addition to treat unresectable BRAF(V600E) mutant
melanomas12, studies on evaluating the effectiveness of vemurafenib
in brain metastases of melanoma (ClinicalTrials.gov identiﬁer
NCT01378975), colorectal cancer15,16 (ClinicalTrials.gov identiﬁer
NCT00405587) and thyroid cancer17 (ClinicalTrials.gov identiﬁer
NCT01709292) are ongoing. Unfortunately, acquired drug resistance
to vemurafenib and relapse among patients were reported frequently
within months of therapy12,14. Identifying and overcoming mechan-
isms that lead to acquired clinical resistance to vemurafenib presents a
signiﬁcant therapeutic challenge18.NH
Cl
F
NH
N
H
O
N
O
F
F
O
Sorafenib
Figure 1 Chemical structures of vemurafenib, dabrafenib and
sorafenib.3. The impact of ATP-binding cassette transporter-mediated
drug transport on cancer chemotherapy
Generally, the success of cancer chemotherapy depends on several
key factors. For an anticancer agent to be effective, a sufﬁcient
amount of the drug must be distributed to the target site(s), which
is dependent on the chemical and biological properties of the
therapeutic agent, as well as the location of the target site(s). Cancer
cells can often acquire resistance through adaptation or spontaneousinduction of certain key regulatory genes during the course of
chemotherapy, which is dependent on the patient, cancer type, stage
of the disease and treatment strategy4,19. Collectively, drug absorp-
tion, distribution and acquired resistance may result in poor response
to chemotherapy and unfavorable patient outcome. Among various
adverse factors in cancer chemotherapy, energy dependent drug
efﬂux and drug compartmentalization are the most common ways
that cancer cells evade drug absorption and drug penetration20,21.
Normally, the ﬁrst line of cellular defense against xenobiotics is to
rapidly reduce the intracellular concentration of xenobiotics by means
of a transporter-mediated efﬂux system. Unfortunately, cancer cells
can utilize the same protective mechanism by up-regulating some of
the drug transporters that reduce drug sensitivity in patients, many of
whom eventually relapse with multidrug-resistant forms of cancer19.
One of the most common causes of acquired drug resistance in cancer
is energy-dependent drug efﬂux by members of the human ATP-
Binding Cassette (ABC) protein superfamily. Human ABC proteins
are subdivided into seven families (ABCA-ABCG), based on
structural and sequence similarities20. Several ABC proteins are
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drug efﬂux. These ABC transporters are membrane proteins, consisting
of transmembrane domains (TMDs) and distinctive nucleotide-binding
domains (NBDs). The TMDs form substrate-binding pockets, while the
NBDs generate energy from ATP hydrolysis to actively transport a
wide range of substrates, including anticancer agents, across biological
membranes, reducing intracellular drug concentration and eventually
resulting in multidrug resistance (MDR)22. ABCA9, ABCB1, ABCB5,
ABCB8, ABCC2, ABCD1 and ABCG2 are some of the ABC proteins
that have been identiﬁed in melanoma cells23–28. In this review, we
focus mainly on the potential roles of ABCB1, ABCG2 and ABCB5 in
limiting the absorption, distribution and penetration of vemurafenib, as
well as in the development of resistance to this drug in cancer cells
expressing a BRAF(V600E) mutation.
3.1. ABCB1
The 170 kDa cell membrane ABCB1 (also known as P-glycoprotein,
P-gp) was the ﬁrst member of the mammalian ABC protein family to
be identiﬁed29. ABCB1 consists of two transmembrane domains,
each containing six α-helices, both linked to ATP-binding domains
that provide energy by hydrolyzing ATP to transport drug substrate
across cell membranes. A large number of classical anticancer agents
including taxanes, Vinca alkaloids, etoposide, teniposide, camptothe-
cins, methotrexate, colchicines, actinomycin D, anthracyclines and
mitoxantrone are well-known drug substrates of ABCB1. More
importantly, many of the newly developed targeted therapy drugs
such as tyrosine kinase inhibitors (TKIs), have been identiﬁed as
substrates of ABCB1 as well30. ABCB1 is expressed in endothelial
cells at the blood–brain barrier (BBB) sites in normal brain tissue and
also in primary brain tumors, and it functions to limit penetration of
the brain by many chemotherapeutics31,32. In addition, ABCB1 is
highly expressed in many normal tissues, including those of the liver
and intestinal walls, signifying the physiological and pharmacological
importance of ABCB120. Moreover, ABCB1 is known to be over-
expressed in many types of cancer and is linked to the MDR
phenotype33. Considering the wide tissue distribution and substrate
speciﬁcity of ABCB1, it is not surprising that ABCB1 plays a key
role in limiting the oral bioavailability of anticancer drugs, preventing
drug distribution and penetration through the blood–brain barrier and
affecting therapeutic outcome in patients19. In terms of melanomas,
endogenous ABCB1 mRNA has been detected in the melanoma cell
lines SK-MEL-28, SK-MEL-5 and M1623,34, as well as non-
cutaneous melanomas35,36. ABCB1 was also detected in a subpopu-
lation of human melanoma cells that co-express ABCB5, hTERT,
and Nanog, and has high self-renewal capacity, representing char-
acteristics of melanoma stem cells37. Interestingly, though the MDR
phenotype has been shown in human BRO melanoma cells
transfected with human ABCB138, the relevance of endogenous
ABCB1 in conferring drug resistance in melanomas has not been
demonstrated yet.
3.2. ABCG2
ABCG2 (also known as breast cancer resistance protein, BCRP; or
placenta-speciﬁc ABC transporter, ABCP; or mitoxantrone resistance
protein, MXR) was identiﬁed in 199839,40. In contrast to ABCB1,
ABCG2 consists of a single ATP-binding domain followed by a
transmembrane domain with six α-helices in a reverse orientation41.
A functional unit of ABCG2 is a dimer or a multimer. Similar to
ABCB1, ABCG2 is overexpressed in many cancers, and is linked toreduced drug accumulation and to the development of MDR in
patients with advanced non-small cell lung cancer or acute myeloid
leukemia (AML)42,43. ABCG2 is capable of transporting a large
variety of anticancer agents such as etoposide, docetaxel, topotecan,
CPT-11, SN-38, methotrexate, ﬂavopiridol, anthracyclines, mitoxan-
trone, and similar to ABCB1, many tyrosine kinase inhibitors
including imatinib, nilotinib, saracatinib and ponatinib30,44,45.
ABCG2 also has a physiological and pharmacological impact on
drug bioavailability, drug distribution, protection of cells or tissues
from xenobiotics and the transport of porphyrins and sterols33.
Similar to ABCB1, ABCG2 has been detected at the luminal
membrane of brain capillaries and the BBB, protecting the brain
from xenobiotics and chemotherapeutics46,47. Studies have shown
that both the protein expression and function of ABCG2 are up-
regulated in neuro-epithelial tumors, restricting penetration of
chemotherapeutics and leading to the development of MDR48,49.
ABCG2 is believed to play a protective role in cancer stem cells
(CSCs) or “side population” cells, with self-renewal properties and
critical roles in tumorigenesis, metastasis and relapse50. Since
ABCG2 is expressed in a wide range of human stem cells, it is
considered as a biomarker for stem cells. ABCG2, along with CD133
and nestin, have been detected in melanomas25,51–53, but the potential
contribution of ABCG2 to chemoresistance in melanomas remains to
be determined. Recently, ABCG2 has been linked to the disease
gout, as mutations (for example Q141K) in this transporter result in
decreased efﬂux of urate from kidney epithelial cells54,55.
3.3. ABCB5
ABCB5 is predominantly expressed in pigment-producing (melano-
genic) melanoma cells23,24. The melanogenesis-related vesicles,
called “melanosomes” are derived from lysosomes and represent a
unique feature of melanomas56,57. Structurally, ABCB5 has 73%
sequence homology with ABCB1 protein24,26. In contrast to ABCB1,
which mediates drug efﬂux from cells, ABCB5 is thought to confer
chemoresistance to cisplatin, doxorubicin and daunorubicin by
intracellular drug sequestration16,24,57,58. Furthermore, studies have
reported that ABCB5 protein expression is up-regulated upon
exposure to the chemotherapeutic drugs dacarbazine (DTIC) and
doxorubicin28,59. Both ABCB1 and ABCG2 are known to be present
in cancer stem cells, and hence are used as stem cell markers60.
Similar cancer stem cell properties were discovered in metastatic
melanoma cells, in which ABCB5 was present61. These ABCB5-
positive melanoma stem cells are not only drug-resistant, but also
possess self-renewal, differentiation and tumorgenic capabilities58,62.
Interestingly, a recent study showed that ABCB5-expressing cells are
resistant to temozolomide, dacarbazine and vemurafenib, suggesting
that ABCB5 may contribute to the drug resistance mechanism, and
thus is a potential therapeutic target for melanoma chemotherapy28.
However, ABCB5-mediated transport of these drugs in melanoma
patient samples has not yet been demonstrated.4. The pharmacological impact of ABC drug transporters
on the bioavailability and distribution of vemurafenib
Reports have shown a high incidence of melanoma metastases in
the brain63,64. Prior to the discovery of vemurafenib, a patient's
response to the standard therapy of interleukin-2 and dacarbazine
was extremely poor14,65. However, in order for vemurafenib to be
effective against brain metastases of melanoma, sufﬁcient amounts
of vemurafenib must ﬁrst be absorbed in the gastrointestinal (GI)
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accumulate in the brain (Fig. 2B). The vasculature structure of the
BBB consists of tightly sealed tight-junction protein complexes
combined with overexpression of several ABC transporters that
actively transport chemotherapeutics back into the bloodstream
(Fig. 2B), making drug penetration of the brain a major obstacle in
chemotherapy66.
A recent study by Mohammed et al.67 reported that the delivery of
vemurafenib to the brain is restricted due to its direct transport by
human ABCB1 and mouse Abcg2 at the blood–brain barrier.
In their in vitro experiments, the intracellular accumulation of
vemurafenib was reduced in MDCKII cells transfected with ABCB1Figure 2 The potential role of multidrug resistance-associated ABC
drug transporters in the oral bioavailability, brain penetration and
therapeutic efﬁcacy of vemurafenib in melanoma and other cancer
cells harboring V600E mutation in BRAF kinase. (A) Highly active
ABCB1 and ABCG2 transporters in intestinal epithelial cells can
signiﬁcantly limit the absorption of vemurafenib into the blood stream,
reducing its bioavailability. (B) The presence of both ABCB1 and
ABCG2 at the blood–brain barrier restricts vemurafenib penetration of
the brain, reducing its effectiveness in patients with brain metastatic
melanoma. (C) The presence of ABCG2 confers resistance to
vemurafenib in BRAF(V600E) mutant A375 melanoma cells. The
role of the ABCB5 transporter in melanoma remains to be evaluated.or ABCG2, as a direct result of ABCB1 and ABCG2-mediated
transport of vemurafenib. Moreover, the ABCB1 and ABCG2-
mediated transport of vemurafenib can be inhibited by zosuquidar
and Ko143, respectively. Furthermore, in their knockout mouse model,
the brain-to-plasma ratios of vemurafenib were increased signiﬁcantly
when Abc1a/1b and Abcg2 were both absent. The authors concluded
that vemurafenib is a substrate of both ABCB1 and ABCG2, and both
transporters play a signiﬁcant role in limiting the central nervous
system (CNS) distribution of vemurafenib. The ﬁndings by
Mohammed et al. were later supported by an independent group.
Durmus et al.68 reported that inhibition of both ABCB1 and ABCG2
could signiﬁcantly improve the bioavailability (Fig. 2A) and brain
penetration (Fig. 2B) of vemurafenib. In their in vitro experiments,
vemurafenib transport mediated by either ABCB1 or ABCG2 was
demonstrated by using MDCK II cells transduced with either human
ABCB1 or ABCG2. The ABCB1- and ABCG2-mediated transport of
vemurafenib was inhibited completely by the ABCB1 inhibitor
zosuquidar and the ABCG2 inhibitor Ko14368. In vivo, the dual
Abcb1a/1b and Abcg2 inhibitor elacridar signiﬁcantly elevated the
plasma levels of vemurafenib and brain accumulation in WT mice to
the same levels as in Abc1a/1b /; Abcg2 / mice. Interestingly,
Durmus et al.68 found that Abcg2 is responsible for reducing the
intestinal uptake of vemurafenib, but limited to a lower oral dose. In
contrast, Abcb1a/1b is accountable for reducing plasma levels of
vemurafenib at later stages. This particular observation is in accordance
with ﬁndings by Chapman et al.14, that in BRAF(V600E) mutant A375
melanoma cells, ABCG2 behaves as a high-afﬁnity but low capacity
transporter of vemurafenib.5. The potential impact of ABC drug transporters on
vemurafenib-based treatment of advanced or metastatic
melanoma
Initial success at using vemurafenib to treat patients with meta-
static and unresectable melanomas or other cancers that carry an
activating BRAF(V600E) mutation was short lived. The rapid
development of acquired resistance to vemurafenib is now
becoming a major obstacle in the treatment of patients diagnosed
with BRAF(V600E)-positive cancer12,14. Multiple mechanisms
involving the reactivation of the mitogen-activated protein kinase
(MAPK) pathway have been reported in vemurafenib-resistant
BRAF(V600E) mutant cancer cells. Up-regulation of CRAF69,70
and overexpression of Tpl2/COT69, RAS activation38,71, enhanced
activation of the FGFR3/RAS pathway72, pathways that lead to
reactivation of ERK signaling73 and activation of RTK signaling
pathways such as IGF-1R or PDGFRβ25,71,74 have all been shown
to contribute to acquired resistance to vemurafenib, depending on
the cancer type17,26.
Recently, we have discovered that in addition to a RAF isoform
switch and activation of various compensatory survival path-
ways25,38,69–74, the overexpression of ABCG2 could also contribute
to the development of acquired resistance to vemurafenib in BRAF
(V600E) mutant cancer cells (Fig. 2C)6. This is not surprising since
the overexpression of ABC transporters is one of the most common
mechanisms of acquired resistance to anticancer agents33. In our study,
the interactions of vemurafenib with three major MDR-associated
ABC drug transporters, ABCB1, ABCC1 and ABCG2 were inves-
tigated. Results showed that vemurafenib binds directly to the
substrate binding pockets of ABCG2, inhibits its function and
stimulates ATP hydrolysis. Similar interactions between vemurafenib
and ABCB1 were observed, but the binding afﬁnity and the
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since vemurafenib binds to the drug binding site of human ABCG2
with relatively high afﬁnity, it effectively inhibited ABCG2-mediated
transport of other drug substrates. Moreover, at non-toxic concentra-
tions, vemurafenib was able to restore chemosensitivity of ABCG2-
overexpressing HEK293 cells to anticancer agents such as mitoxan-
trone and topotecan. Similarly, vemurafenib also restored the sensi-
tivity of drug-resistant ABCG2-overexpressing and also expressing
(V600E) mutant BRAF A375 melanoma cells to mitoxantrone6. In
contrast, no interaction was detected between vemurafenib and
ABCC1 protein. Moreover, 72 h of vemurafenib treatment had no
signiﬁcant effect on the expression of ABCB1, ABCC1 or ABCG2
protein in cancer cells expressing wild-type BRAF. Surprisingly, while
overexpression of human ABCG2 had no effect on the chemosensi-
tivity of wild-type BRAF cancer cells to vemurafenib, the ectopic
expression of human ABCG2 led to vemurafenib resistance in A375
melanoma cells harboring the BRAF(V600E) mutation. We found that
in A375 melanoma cells, BRAF kinase inhibition by vemurafenib was
signiﬁcantly reduced in the presence of functional ABCG2, implicat-
ing ABCG2-mediated efﬂux as a mechanism of resistance for
vemurafenib6. Unfortunately, it is still unknown whether prolonged
treatment with vemurafenib leads to overexpression of ABC drug
transporters in BRAF(V600E) melanoma, thyroid or colorectal
cancers. Furthermore, the potential impact of ABCB1 or ABCB5 or
other MDR-associated ABC drug transporters on the therapeutic
outcome using vemurafenib in melanomas or other cancers harboring
the BRAF(V600E) mutation needs to be determined.6. Impact of ABC drug transporters on treatment with other
BRAF inhibitors (dabrafenib and sorafenib)
Dabrafenib (GSK2118436) is a new BRAF inhibitor (Fig. 1)
designed to target melanomas expressing V600E and V600K mutant
BRAF. Good clinical response rates have been observed in metastatic
melanoma (including brain metastases) patients receiving dabrafe-
nib75,76, but cases of acquired resistance to dabrafenib have also been
reported77–79. Although the link between ABC drug transporters and
acquired resistance to dabrafenib is still lacking, a recent study using
MDCKII cells indicated that dabrafenib is a substrate of both ABCB1
and ABCG280. Moreover, Mittapalli et al.80 showed that in both
in vivo and intact BBB models, the dabrafenib brain distribution is
limited by the function of both ABCB1 and ABCG2. In contrast to
vemurafenib and dabrafenib, sorafenib is a nonselective BRAF
inhibitor (Fig. 1) that targets both BRAF and CRAF, and inhibits
other multiple kinases81. A phase I/II clinical trial reported that in
metastatic melanoma patients, combination therapy of sorafenib,
carboplatin and paclitaxel demonstrated a better response rate and
longer progression-free survival than with standard chemotherapy82.
Like vemurafenib and dabrafenib, the interactions between sorafenib,
ABCB1 and ABCG2 have been demonstrated by several independent
groups. Other studies have reported that sorafenib is transported by
both ABCB183,84 and ABCG2, but more efﬁciently by ABCG284,
and consistent with these ﬁndings the penetration of the brain by
sorafenib was signiﬁcantly higher in Abcg2 / mice than in WT84,85.7. Conclusions
Collectively, the actions of ABCB1 and ABCG2 in the GI tract
and at the BBB contribute signiﬁcantly to reduced oral bioavail-
ability and limit the penetration of the brain by vemurafenib(Fig. 2A and B), which is a major obstacle when treating patients
with melanoma brain metastases. The clinical application of a dual
ABCB1 and ABCG2 inhibitor such as elacridar could possibly
provide a solution to increase the oral bioavailability and enhance
brain penetration of vemurafenib in patients with brain metastatic
melanoma86. At the cellular level, the presence of MDR-associated
ABC drug transporters may present new therapeutic challenges
when treating cancers expressing the V600E mutant version of
BRAF kinase. The ability of ABC drug transporters to effectively
reduce the intracellular concentration of vemurafenib in cancer
cells can potentially lead to acquired resistance to this drug
(Fig. 2C). Moreover, the reported high afﬁnity of vemurafenib
for binding to ABCG2 suggests the potential use of vemurafenib
as a chemosensitizer that would work alongside classical antic-
ancer agents to treat ABCG2-positive MDR cancers. Consistent
with these ﬁndings, vemurafenib was found to dock in the drug-
binding pocket of the homology model of human ABCB1 and
ABCG2 and also modulate the function of the ABCC10 (MRP 7)
transporter87. Thus, we propose that simultaneous administration
of vemurafenib and protein kinase inhibitors targeting key signal-
ing pathways that are involved in the development of acquired
resistance to vemurafenib25,38,69–74, as well as inhibiting the
actions of ABC drug transporters in BRAF(V600E) mutant
cancers33, may offer great promise for effective treatment of
melanoma patients.Acknowledgments
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